Skip to main content
    B

    BioAge Labs, Inc (BIOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.10
    -0.12 (-2.30%)

    Market Cap: $239.87M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    BioAge Labs, Inc (BIOA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    BioAge Labs (BIOA) has a market cap of $239.87M and an enterprise value of $187.20M. It kept -1253.60% of revenue as net income over the last 12 months. Its share count is up 28.07% from a year earlier.

    Total Valuation

    Enterprise value is 21.96% below the market cap, as cash exceeds debt.

    Market Cap$239.87M
    Enterprise Value$187.20M
    Latest price (Nov 17, 2026)$5.10

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.39% in the quarter ended Sep 30, 2026 and grew 262.46% a year over 2 years.

    Shares Outstanding45.91M
    Shares Change (YoY)+28.07%
    Shares Change (QoQ)+2.39%
    Share Count Growth (2Y CAGR)+262.46%

    Valuation Ratios

    Sales and book value multiples are 27.2x and 0.7x.

    P/S Ratio27.2x
    Forward P/S34.7x
    P/B Ratio0.7x

    Price Statistics

    The stock is down 34.62% over 52 weeks and trades 20.68% below its 50-day average.

    Beta (1Y)1.70
    52-Week Change-34.62%
    1-Month Change+2.20%
    3-Month Change-52.56%
    6-Month Change-68.85%
    Total Return (1Y)-34.62%
    Return vs SPY (1Y)-49.74%
    Max Drawdown (1Y)-80.72%
    Max Drawdown (3Y)-88.23%
    Sharpe Ratio (1Y)-0.37
    Correlation with SPY (1Y)0.18
    50-Day Average$6.43
    200-Day Average$14.97
    52-Week Range$4.81 to $25.95
    RSI (14 Days)35.8
    Average Volume (20 Days)679.93K

    Price chart

    Financial Position

    Current assets cover 15.51x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio15.51x
    Quick Ratio15.51x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -31.12% and return on assets is -29.32% over the last 12 months.

    Return on Equity (ROE)-31.12%
    Return on Assets (ROA)-29.32%
    Asset Turnover0.03x
    Receivables Turnover14.45x

    Scores

    BIOA has an Altman Z-Score of 4.89, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score4.89
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $8.60M over the last 12 months is up 45.33% from the 12 months before.

    Revenue$8.60M
    Revenue Growth (YoY)+45.33%
    Gross Profit$8.60M
    Operating Income-$120.54M
    Pretax Income-$107.27M
    Net Income-$107.80M
    Reported EPS (TTM)-$2.55

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 94.23% of the $367.65M in total assets.

    Cash and Equivalents$52.67M
    Total Debt$0
    Net Cash$52.67M
    Net Cash Per Share$1.15
    Working Capital$276.03M
    Shareholder Equity$346.45M
    Book Value Per Share$7.55
    Total Assets$367.65M
    Total Liabilities$21.20M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $484.00K of capital spending, operating cash flow left -$103.00M of free cash flow.

    Operating Cash Flow-$102.52M
    Capital Expenditures$484.00K
    Free Cash Flow-$103.00M
    FCF Per Share-$2.24
    Depreciation and Amortization$1.79M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1401.81%.

    Gross Margin100.00%
    Operating Margin-1401.81%
    Pretax Margin-1247.46%
    Net Margin-1253.60%
    FCF Margin-1197.81%

    Dividends and Yields

    BIOA does not pay a dividend. Its free cash flow yield is -43.99%.

    FCF Yield-43.99%
    Buyback Yield-66.90%
    Shareholder Yield-66.90%

    Peer Position

    Against 8 similar companies, BIOA has the highest P/S.

    P/S Ratio27.2x vs 1.0x median
    Revenue Growth (Trailing 4 Quarters, YoY)+45.33% vs +12.08% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BIOA

    What is BIOA's market cap?

    BioAge Labs has a market cap of $239.87M. Its enterprise value, which adds debt and subtracts cash, is $187.20M.

    How many shares of BIOA are outstanding?

    BioAge Labs has 45.91M shares outstanding. The count is up 28.07% from a year earlier.

    Does BIOA pay a dividend?

    No. BioAge Labs does not pay a dividend.

    How much debt does BIOA have?

    BioAge Labs has $0 of total debt and $52.67M of cash and equivalents, a net cash position of $52.67M.